BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence
BioNTech's mRNA cancer vaccine, BNT113, failed to improve progression-free survival in a phase 2/3 trial involving advanced HPV16-positive head and neck cancer. The trial will continue to assess overall survival. This setback raises questions about the clinical promise of therapeutic mRNA technology. BioNTech's stock fell after the announcement.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ BioNTech's mRNA cancer vaccine, BNT113, failed to improve progression-free survival in a phase 2/3 trial.
- ✓ The trial involved advanced HPV16-positive head and neck cancer patients.
- ✓ BioNTech's stock fell after the announcement of the trial's failure.
- ✓ The trial will continue to assess overall survival.
What changed
BioNTech announced that its experimental cancer immunotherapy BNT113 failed to significantly delay disease progression in a Phase 2/3 trial.
Live updates
-
BioNTech's mRNA cancer vaccine fails phase 3 test
BioNTech's mRNA cancer vaccine, BNT113, failed to improve progression-free survival in a phase 2/3 trial involving advanced HPV16-positive head and neck cancer. The trial will continue to assess overall survival. This setback raises questions about the clinical promise of therapeutic mRNA technology. BioNTech's stock fell after the announcement.
Why it matters
This failure is a significant setback for BioNTech, which had been working to apply mRNA technology to cancer treatments. The company's stock price has been affected by the news. The trial's outcome may impact the future of BioNTech's cancer research and the broader field of mRNA-based therapies. The failure highlights the challenges of developing effective cancer treatments.
What is confirmed
- BioNTech's mRNA cancer vaccine, BNT113, failed to improve progression-free survival in a phase 2/3 trial.
- The trial involved advanced HPV16-positive head and neck cancer patients.
- BioNTech's stock fell after the announcement of the trial's failure.
- The trial will continue to assess overall survival.
Still unconfirmed
- Analysts say that an overall survival win is now less likely.
What to watch next
- The final results of the trial, particularly the overall survival outcome
- BioNTech's future research and development plans for its mRNA-based therapies
- The impact of this failure on the company's stock price and investor confidence
confidence 85%Sources used for this update (13)
- Fierce Biotech — BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence
- Yahoo Finance — BioNTech stock falls after cancer trial misses key endpoint
- Reuters — BioNTech's mRNA cancer therapy misses first goal in head and neck trial
- OncLive — Tenumomeran/Raplemomeran Plus Pembrolizumab Misses PFS End Point in HPV16+ HNSCC
- The Globe and Mail — Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success?
- BioSpace — BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival
- www.myasset.com — Sector News & Data
- www.biotech-now.co.uk — BioNTech's mRNA cancer vaccine fails phase 3 test ...
- www.biospace.com — BioNTech faces 3rd mRNA setback as head and neck cancer ...
- lifescivoice.com — BioNTech's Cancer Vaccine Fails Phase 3 Trial Results
- www.trialsitenews.com — BioNTech’s Cancer mRNA Bet Hits a Wall: Phase 3 Trial Misses ...
- www.bioreview.com — BioNTech's mRNA Cancer Vaccine Failure: Fixed vs. Flexible ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community